127828-22-2

Basic information

• Product Name: Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI);CarbaMic acid, [2-(2-aMinoethoxy)ethyl]-, 1,1-diMethylethyl ester;3-Oxapentane-1,5-diamine, N-BOC protected, 2-(2-Aminoethoxy)ethylamine, N-BOC protected;tert-Butyl [2-(2-aminoethoxy)ethyl]carbamate;N-Boc-2-(2-Aminoethoxy)ethanamine;N-Boc-2-aminoethyl 2-aminoethyl ether;BocNH-PEG1-CH2CH2NH2;[2-(2-aMinoethoxy)ethyl]-, 1,1-diMethylethyl ester
• CAS NO: 127828-22-2
• Molecular Formula: C₉H₂₀N₂O₃
• Molecular Weight: 204.2667
• EINECS: 1533716-785-6
• Product Categories: N-BOC
• Mol File: 127828-22-2.mol

Chemical Properties

• Boiling Point: 321.128°C at 760 mmHg
• Flash Point: 148.013°C
• Appearance: /
• Density: 1.024g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.4560 to 1.4600
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.24±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(127828-22-2)
• EPA Substance Registry System: Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(127828-22-2)

Safety Data

• Hazardous Substances Data: 127828-22-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a reagent for the synthesis of various pharmaceutical compounds. Its reactive amino group allows for the formation of amide bonds with carboxylic acids, which is a common strategy in drug development. The Boc protection group also provides an additional level of control over the reactivity of the molecule, enabling selective deprotection and functionalization.
Used in Chemical Synthesis:
In the field of chemical synthesis, Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a building block for the creation of more complex molecules. Its reactive amino group can be used to form amide bonds with other molecules, allowing for the construction of a wide range of chemical structures. The Boc protection group also provides a means of controlling the reactivity of the molecule, enabling the synthesis of more complex structures with greater precision.
Used in Bioconjugation:
Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a bioconjugation reagent, allowing for the attachment of various biomolecules, such as proteins, peptides, and nucleic acids, to other molecules or surfaces. The reactive amino group can form stable covalent bonds with carboxylic acid-containing biomolecules, while the Boc protection group can be removed under mild acidic conditions to reveal the free amine, facilitating the conjugation process.
Used in Drug Delivery Systems:
In the development of drug delivery systems, Carbamic acid, [2-(2-aminoethoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) can be used as a component in the design of targeted drug carriers. The reactive amino group can be used to attach drug molecules or targeting ligands to the carrier, while the Boc protection group can be removed to control the release of the drug or to facilitate the binding of the targeting ligand to its specific receptor.

InChI:InChI=1/C9H20N2O3/c1-9(2,3)14-8(12)11-5-7-13-6-4-10/h4-7,10H2,1-3H3,(H,11,12)

Upstream product

• 2752-17-2 2,2'-diaminodiethyl ether 
• 24424-99-5 di-tert-butyl dicarbonate 
• 60792-79-2 2-(2-aminoethoxy)ethanamine dihydrochloride 
• 176220-30-7 1-(2-(tert-Butoxycarbonylamino)ethoxy)-2-azidoethane 
• 1046804-80-1 Tert-butyl 2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethylcarbamate 
• 139115-91-6 2-(2-tert-butyloxycarbonylaminoethoxy)ethanol 
• 302331-20-0 methanesulfonic acid 2-(2-tert-butoxycarbonylamino-ethoxy)-ethyl ester 

Downstream Products

• 632323-84-3 N-(2-(tert-butoxycarbonylamino)ethoxyethyl) N_α-benzyloxycarbonyl-D-arginine amide 
• 943249-85-2 C₃₉H₇₂O₁₂N₆ 
• 950830-76-9 C₃₆H₆₆N₆O₁₂ 
• 950830-78-1 C₃₆H₆₀N₆O₁₂ 
• 887150-21-2 {2-[2-(pentafluorophenylmethyl-amino)-ethoxy]-ethyl}-carbamic acid tert-butyl ester 
• 1228371-44-5 C₁₇H₂₆N₂O₅ 
• 1235236-32-4 tert-butyl 2-(2-(2-hydroxybenzamido)ethoxy)ethylcarbamate 
• 1281971-05-8 tert-butyl 2-(2-(2-methyl-3-oxo-2-phenyl-2,3-dihydrofuran-5-carboxamido)ethoxy)ethylcarbamate 
• 1286173-97-4 tert-butyl 2-(2-(2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamido)ethoxy)ethylcarbamate 
• 1359745-84-8 C₁₅H₂₂N₄O₇ 
• 1429628-73-8 tert-butyl 2-(2-(2-(2′-ethoxybiphenyl-4-yl)-6-fluoro-3-methylquinoline-4-carboxamido)ethoxy)ethylcarbamate 

Relevant articles and documents

Macrocyclic DNA-mismatch-binding ligands: Structural determinants of selectivity

A collection of 15 homodi- meric and 5 heterodimeric macrocyclic bisintercalators was prepared by one- or two-step condensation of aromatic dialdehydes with aliphatic diamines; notably, the heterodimeric scaffolds were synthesized for the first time. The binding of these macrocycles to DNA duplexes containing a mispaired thy- mine residue (TX), as well as to the fully paired control (TA), was investi- gated by thermal denaturation and flu- orescent-intercalator-displacement experiments. The bisnaphthalene derivatives, in particular, the 2, 7-disubstituted ones, have the highest selectivity for the TX mismatches, as these macrocy- cles show no apparent binding to the fully paired DNA. By contrast, other macrocyclic ligands, as well as seven conventional DNA binders, show lesser or no selectivity for the mismatch sites. The study demonstrates that the topology of the ligands plays a crucial role in determining the mismatch-binding affinity and selectivity of the macrocy- clic bisintercalators. 2010 Wiley-VCH Verlag GmbH & Co. KGaA.

Development of novel cyclic peptides as pro-apoptotic agents

Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.

Specific fluorescence labeling of target proteins by using a ligand-4-azidophthalimide conjugate

We herein propose a simple affinity-labeling method using a ligand-4-azidophthalimide (AzPI) conjugate. As a proof of concept, we show that two different ligand-AzPI conjugates enabled highly specific fluorescence labeling of their individual target proteins even in crude cell lysates. This method was also applied to label endogenous target proteins inside living cells.

Facile synthesis and evaluation of C-functionalized benzyl-1-oxa-4,7,10- triazacyclododecane-N,N′,N″-triacetic acid as chelating agent for 111In-labeled polypeptides

A 12-membered polyazamacrocycle, 1-oxa-4,7,10-triazacyclododecane-N, N′,N″-triacetic acid (ODTA), has been reported to provide an indium chelate of net neutral charge with thermodynamic stability higher than 1,4,7,10-tetraazacyclododecane-N,N′,N″,N?-tetra

Synthesis and evaluation of a pseudocyclic tristhiourea-based anion host

A novel methodology for the evaluation of receptor arrangement in structurally flexible anion chemosensors was developed and applied to map the binding site of a new pseudocyclic tristhiourea chemosensor (6). The syntheses of 6 and related macrocyclic chemosensor 10 (a model of the folded monomeric structure of 6) are reported. Both chemosensors were evaluated by titration with a variety of structurally different anions in CH3Cl and DMSO, showing a common preference for F-, CH3CO2 -, and H2PO4-. However, within this group of anions, the binding patterns of the chemosensors differed, indicating dissimilarity in the arrangement of the binding sites of 6 and 10.

LIGAND DRUG CONJUGATES AND MODIFIED BET INHIBITORS

A ligand drug conjugate comprising a) a targeting ligand; b) a cleavable bridge; and a bromodomain and extraterminal (BET) inhibitor is provided. The targeting ligand may comprise a cancer targeting ligand. The BET inhibitor may comprise I-BET762, (+)-JQ1, MS417, OXT015, (2), RVX-208, (3), OXFBD02, OXFBD03, I-BET151, (4), PFI-1, I-BET726, MS436, XD14 or a modified BET inhibitor. Modified BET inhibitors are also provided, including RT48 ((S) -2- (6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f] [1,2,4] triazolo [4,3-a] [1,4] diazepin-4-yl)-1-(4-(dimethylamino) piperidin-1-yl) ethan-1-one) and RT53 ((S) -2- (6- (4-chlorophenyl) -8-methoxy-1-methyl-4H-benzo[f] [1,2,4] triazolo [4,3-a] [1,4] diazepin-4-yl) -N-(4- (4- (dimethylamino) piperidin-1-yl) phenyl) acetamide). A pro-drug of a BET inhibitor is also provided. A method of preparing a ligand drug conjugate according to the invention is also provided. The method comprises i) functionalising a BET inhibitor with a tertiary amine to form a modified BET inhibitor according to the invention; ii) bonding the modified BET inhibitor formed in step i) to a cleavable bridge; and iii) bonding the cleavable bridge bound to the modified BET inhibitor formed in step ii) to a targeting ligand. A ligand drug conjugate according to the invention for use as a medicament is also provided.

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.

Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs

The human tyrosinase is the most prominent therapeutic target for pigmentary skin disorders. However, the overwhelming majority efforts have been devoted to search mushroom tyrosinase inhibitors, which show poor inhibitory activity on human tyrosinase and certain side effects that cause skin damage in practical application. Herein, a series of degraders that directly targeted human tyrosinase was firstly designed and synthesized based on newly developed PROTAC technology. The best PROTAC TD9 induced human tyrosinase degradation obviously in dose and time-dependent manner, and its mechanism of inducing tyrosinase degradation has also been clearly demonstrated. Besides, encouraging results that low-toxicity PROTAC TD9 was applied to reduce zebrafish melanin synthesis have been obtained, highlighting the potential to treatment of tyrosinase-related disorders. Moreover, this work has innovatively expanded the application scope of PROTAC technology and laid a solid foundation for further development of novel drugs treating pigmentary skin disorders.

A MedChem toolbox for cereblon-directed PROTACs

A modular chemistry toolbox was developed for cereblon-directed PROTACs. A variety of linkers was attached to a CRBN ligand via the 4-amino position of pomalidomide. We used linkers of different constitution to modulate physicochemical properties. We equipped one terminus of the linker with a set of functional groups, e.g. protected amines, protected carboxylic acids, alkynes, chloroalkanes, and protected alcohols, all of which are considered to be attractive for PROTAC design. We also highlight different opportunities for the expansion of the medicinal chemists' PROTAC toolbox towards heterobifunctional molecules, e.g. with biotin, fluorescent, hydrophobic and peptide tags.

Evaluation of linker length effects on a BET bromodomain probe

Fueled by the therapeutic potential of the epigenetic machinery, BET bromodomains have seen high interest as drug targets. Herein, we introduce different linkers to a BET bromodomain benzodiazepine ligand (I-BET762) to gauge its implications in the develo